Investor
Ideas #Potcasts: #Cannabis News and Stocks on the Move; (CSE:
$AGRA.C), (CSE: $THC.C), (CSE: $MYM.C), (TSXV: $KHRN.V)
Delta, Kelowna, BC –April 9,
2019 (Investorideas.com Newswire) www.Investorideas.com, a global news source
covering leading sectors including marijuana and hemp stocks and its potcast
site, www.potcasts.ca release today’s edition of Investorideas.com potcastsCM -
cannabis news and stocks to watch plus insights from thought leaders and
experts.
Listen to the podcast:
Read this in full
at https://www.investorideas.com/news/2019/cannabis-potcasts/04091AGRA-THC-MYM-KHRN.asp
Today’s podcast overview/transcript:
Good
afternoon and welcome to another Investorideas.com “potcast” looking at
cannabis news, stocks to watch as well as insights from experts and industry
leaders.
Today
we are looking at announcements from AgraFlora Organics International Inc., THC BioMed Intl Ltd., MYM
Nutraceuticals Inc. and Khiron Life Sciences Corp..
AgraFlora Organics International Inc., (CSE:
AGRA) (OTC:
PUFXF) a growth oriented and diversified
international cannabis company, and ICC
International Cannabis Corp., have entered into an agreement
whereby AgraFlora will transfer its portfolio of exotic, native Colombian
cannabis genetics to ICC for international marketing and distribution purposes.
In May 2018, AgraFlora formed a wholly
owned subsidiary, Pure Grow Medicinals S.A.S., to pursue cannabis cultivation
and genetics opportunities in Colombia. Pure Grow has since been working in
concert with a Cannabis Cup winner whose strain "Medellin Gold" has
received industry accolade and has, since formation, acquired a select library
of rare and exotic native cannabis seed varieties from various regions in the
country.
"This partnership further equips
International Cannabis with the ability to provide highly coveted Colombian
cannabis flower to its global distribution network of approximately 39,000
pharmacies and retail outlets," said Eugene Beukman, Chief Executive
Officer and a Director of International Cannabis. "The transfer of these native
Colombian strains will also allow for the continued differentiation of the
International Cannabis brand in an increasingly generic and homogenized
market."
THC BioMed Intl Ltd. (CSE:THC), announced that
it has received Health Canada permission to commence cannabis production in two
additional strata lots at THC BioMed's flagship location in Kelowna, B.C.
The newly licensed strata lots will allow
THC to begin automation of its systems allowing more efficient production,
while increasing margins.
THC now has 11 strata lots licensed for
production, 3 additional strata lots are being submitted for review by Health
Canada, while a further 3 strata lots are currently under construction.
"While scale is essential in the
development of a conglomerate, we need to properly asses the margins. We are
streamlining systems to ensure quality is maintained while focusing on long
term prosperity and viability," commented THC's Chief Financial Officer,
Hee Jung Chun.
MYM Nutraceuticals Inc. (CSE:
MYM) (OTCBB:
MYMMF) announced that
it has entered into a memorandum of understanding with Aqueous Sciences of
Nevada, a wholly owned subsidiary of One World Ventures Inc.(OTC: OWVI), to
grow 3,000 acres of hemp on Navajo Nation land located near the four corners
area of Colorado, Arizona, Utah and New Mexico, USA.
MYM and Aqueous will incorporate a new
company for the purpose of cultivating, extracting, and distributing hemp on 3,000
acres in New Mexico. Aqueous is the sole exclusive agent for the Navajo Nation,
managing companies that wish to cultivate hemp on Navajo Nation land. MYM and
Aqueous will work on an exclusive basis and will each own 50% of the new
company. MYM and Aqueous plan to extend their activities to include extracting,
manufacturing and distribution of hemp based products that will comply with
Navajo Nation, USDA, FDA and FTC regulations and requirements.
"With the recent passing of the Farm
Bill in the US, CBD-rich hemp was removed from the classified drug list,
opening the door for farmers to legally grow hemp," said Howard Steinberg,
CEO of MYM. "Our partnership with Aqueous is in keeping with our new
strategic plan to become a global leader in the cultivation, extraction and
distribution of hemp and CBD in bulk and for use in our own unique branded
products."
Khiron Life Sciences Corp. (TSXV:
KHRN), (OTCQB:
KHRNF ), an integrated medical cannabis
company with its core operations in Latin America, announced
today that it has signed a definitive
agreement for the acquisition of NettaGrowth International Inc., as previously
announced on January 25, 2019. NettaGrowth will, at the time of the closing of
the acquisition, own all of the outstanding shares of Dormul S.A., a Uruguayan
company that has obtained the first licence to produce and export medical
cannabis with THC for commercialization in Uruguay. As consideration for the
acquisition of NettaGrowth, on closing, Khiron will issue 8,498,821 common
shares to the shareholders of NettaGrowth at a deemed price of $1.61 per common
share.
Alvaro Torres, CEO of Khiron, comments
"This acquisition adds considerable capacity and product diversity
potential to the Khiron portfolio of assets. As the first country to legalize
cannabis for adult use purposes, these Uruguayan licences provide us the
opportunity to address a broader demographic of consumers and export products
to key regions of the world. Compared to the extract-only medical market of
Colombia, the Uruguayan regulations permit the domestic and international
distribution of flower. This is an excellent complement to our product focus in
Colombia. I would like to thank all individuals involved in finalizing this
definitive agreement and look forward to moving this transaction to
close."
Uruguay was the first country to
establish legislation for cannabis and Dormul has secured a medical cannabis
cultivation and commercialization licence for the jurisdiction, with a
cultivation capacity of up to 120 tonnes and 170,000 plants. In addition,
Dormul has an application pending for an extraction licence. Upon receipt of
its extraction licence, Dormul is expected to become the first company in
Uruguay to be approved for medical cannabis-based CBD oils for both domestic
and export purposes. With a strong commitment to research and development,
Dormul has established a strategic partnership with the prestigious Institut
Pasteur de Montevideo, a prestigious foundation formed between the Uruguayan
and French governments focused on the research and development of cannabis
product. The foundation was recently recognized by the Uruguayan Ministry of
Industry for the important social and economic impact its operations are
anticipated to have for the country.
Investor ideas reminds all listeners to read our disclaimers and
disclosures on the
Investorideas.com website and this podcast is not an endorsement
to buy products or services or securities. Investors are reminded all
investment involves risk and possible loss of investment
Subscribe to the new cannabis podcast series:
Investorideas.com podcasts are also
available on iTunes, Spotify, Google
Play Music, Stitcher, Spreaker, YouTube
via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified word mark Trademark
on the blockchain through Cognate, Inc. CM Certification-Registration Number:
10468217708
About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a recognized news
source publishing third party news and press releases plus we create original
financial content. Learn about investing in stocks and sector trends
from Investorideas.com with our news alerts , articles , podcasts and videos talking about cannabis, crypto,
technology including AI and IoT ,
mining ,sports biotech, water, renewable energy and more . Investorideas.com
original branded content includes the daily Crypto Corner and Podcast, Play
by Play sports and stock news column, Investor Ideas #Potcasts #Cannabis News
and Stocks on the Move podcast and column,
Cleantech and Climate Change Podcast and
the AI
Eye Podcast and column covering developments in
AI.
Disclaimer/Disclosure: Investorideas.com is a digital publisher
of third party sourced news, articles and equity research as well as creates
original content, including video, interviews and articles. Original content
created by investorideas is protected by copyright laws other than syndication
rights. Our site does not make recommendations for purchases or sale of stocks,
services or products. Nothing on our sites should be construed as an offer or
solicitation to buy or sell products or securities. All investment involves
risk and possible loss of investment. This site is currently compensated for
news publication and distribution, social media and marketing, content creation
and more. Contact each company directly regarding content and press release
questions. Disclosure is posted for each compensated news release, content
published /created if required but otherwise the news was not compensated for
and was published for the sole interest of our readers and followers.
Learn more about Investor ideas podcast
and news publication services and costs https://www.investorideas.com/News-Upload/
Global investors must adhere to
regulations of each country.
Please read Investorideas.com privacy
policy: https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use
of cannabis except where permissible by law. Our site does not possess,
distribute, or sell cannabis products.
Follow us on Social Media
Contact Investorideas.com
800-665-0411
No comments:
Post a Comment